Skip navigation
Skip navigation

Pharmaceuticals, Intellectual Property and Free Trade: The Case of the US-Australia Free Trade Agreement

Drahos, Peter; Lokuge, Buddhima; Goddard, Martyn; Henry, David A; Faunce, Thomas

Description

Australia did poorly in several key areas of the recently completed free trade agreement with the US. It failed to insulate the Pharmaceutical Benefits Scheme (PBS) from significant change, and conceded to increased intellectual property standards. The PBS, as a system of effective bargaining with multinational pharmaceutical firms, has been deeply compromised and higher drug prices can be expected over time. The intellectual property chapter strengthens the position of patent owners and...[Show more]

dc.contributor.authorDrahos, Peter
dc.contributor.authorLokuge, Buddhima
dc.contributor.authorGoddard, Martyn
dc.contributor.authorHenry, David A
dc.contributor.authorFaunce, Thomas
dc.date.accessioned2015-12-13T22:50:55Z
dc.date.available2015-12-13T22:50:55Z
dc.identifier.issn0810-9028
dc.identifier.urihttp://hdl.handle.net/1885/81027
dc.description.abstractAustralia did poorly in several key areas of the recently completed free trade agreement with the US. It failed to insulate the Pharmaceutical Benefits Scheme (PBS) from significant change, and conceded to increased intellectual property standards. The PBS, as a system of effective bargaining with multinational pharmaceutical firms, has been deeply compromised and higher drug prices can be expected over time. The intellectual property chapter strengthens the position of patent owners and undermines the evolution of a competitive generics industry. These developments are part of a broader and internationally coordinated strategy being pursued by pharmaceutical multinationals to globalize and strengthen patent rights and monopoly profits.
dc.publisherCarfax Publishing, Taylor & Francis Group
dc.sourcePrometheus
dc.subjectKeywords: free trade; intellectual property rights; multinational enterprise; pharmaceutical industry; trade agreement; Australasia; Australia; North America; United States Bargaining; Free trade agreements; Intellectual property; Pharmaceutical benefits scheme
dc.titlePharmaceuticals, Intellectual Property and Free Trade: The Case of the US-Australia Free Trade Agreement
dc.typeJournal article
local.description.notesImported from ARIES
local.description.refereedYes
local.identifier.citationvolume22
dc.date.issued2004
local.identifier.absfor180115 - Intellectual Property Law
local.identifier.ariespublicationMigratedxPub9346
local.type.statusPublished Version
local.contributor.affiliationDrahos, Peter, College of Asia and the Pacific, ANU
local.contributor.affiliationLokuge, Buddhima, College of Asia and the Pacific, ANU
local.contributor.affiliationFaunce, Thomas, ANU College of Law, ANU
local.contributor.affiliationGoddard, Martyn, Australian Consumers Association
local.contributor.affiliationHenry, David A, University of Newcastle
local.bibliographicCitation.issue3
local.bibliographicCitation.startpage243
local.bibliographicCitation.lastpage257
local.identifier.doi10.1080/0810902042000255705
dc.date.updated2015-12-11T10:42:50Z
local.identifier.scopusID2-s2.0-4644226808
CollectionsANU Research Publications

Download

There are no files associated with this item.


Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  19 May 2020/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator